SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Jul 11, 2012
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: July 11, 2012 · CIK: 0001137883 · Accession: 0001144204-12-039033
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-179331
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Laura Crotty, Esq. BrainStorm Cell Therapeutics Inc. Amendment No. 4 to the Registration Statement on Form S-1 (Registration No. 333-179331) Acceleration Request
Dear Ms. Crotty:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, BrainStorm Cell Therapeutics Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Amendment No. 4 to the Registration Statement on Form S-1 be accelerated to Friday, July 13, 2012, at 9:30 a.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
● should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Any questions regarding this request should be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.
Very truly yours,
BrainStorm Cell Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
BRAINSTORM CELL THERAPEUTICS INC.
605 Third Avenue, 34th Floor
New York, New York 10158
July 11, 2012
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Laura Crotty, Esq.
RE:
BrainStorm Cell Therapeutics Inc.
Amendment No. 4 to the Registration Statement
on
Form S-1 (Registration No. 333-179331)
Acceleration Request
Dear Ms. Crotty:
Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, BrainStorm Cell Therapeutics Inc. (the “Company”) hereby
respectfully requests that the effectiveness of the above-captioned Amendment No. 4 to the Registration Statement on Form S-1 be
accelerated to Friday, July 13, 2012, at 9:30 a.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
●
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Any questions regarding this request should
be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.
Very truly yours,
BrainStorm Cell Therapeutics Inc.
/s/ Liat Sossover
By: Liat Sossover
Its: Chief Financial Officer
cc:
Thomas B. Rosedale, Esq
(BRL Law Group LLC)